Degradation of recombinant proteins of diverse formats by CHO host cell proteases is circumvented via knock-out of CHO matriptase

An increasing number of biologics are entering the pipeline of pharmaceutical companies. Today, the preferred production host for therapeutic proteins are CHO cells. However one of the major hurdles especially for the production of non-antibody glycoproteins is host cell-related proteolytic degradation which can drastically impact developability and timelines of pipeline projects.